Found 285 articles for: "biologics"
Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
August 2022 | Volume 21 | Issue 8 | Editorials | 914 | Copyright © August 2022
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis...
Read MoreAdherence and Persistence to Acne Medications: A Population-Based Claims Database Analysis
July 2022 | Volume 21 | Issue 7 | Original Article | 758 | Copyright © July 2022
Background: The chronicity of acne and its treatment with topicals contribute to poor treatment adherence and persistence. How well newly diagnosed acne patients use their treatment i...
Read MoreSubgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 659 | Copyright © June 2022
Background: Biologic drugs are generally recommended for treating moderate-to-severe psoriasis. While eligibility criteria are primarily defined by clinical treatment guidelines, acce...
Read MoreProbiotics Supplementation Improves Quality of Life, Clinical Symptoms, and Inflammatory Status in Patients With Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 637 | Copyright © June 2022
Background: Studies have proposed a link between psoriasis and imbalanced gut microbiome. Therefore, the modulation of the gut microbiota with probiotics may improve clinical outcomes...
Read MoreThe Use of Bakuchiol in Dermatology: A Review of In Vitro and In Vivo Evidence
June 2022 | Volume 21 | Issue 6 | Original Article | 624 | Copyright © June 2022
The plant Psoralea corylfolia contains compounds such as psoralens that are useful for the treatment of psoriasis and vitiligo, and the plant is used in Chinese and Indian traditional medicin...
Read MoreEvidence Threshold for a Precision Medicine Test that Predicts Optimal Response to a Biologic Agent in Patients With Psoriasis: A Consensus Panel
June 2022 | Volume 21 | Issue 6 | Original Article | 630 | Copyright © June 2022
Precision medicine approaches are receiving increased attention in dermatology, including inflammatory skin diseases. In psoriasis, a precision medicine treatment paradigm could temper the rapid incre...
Read MoreAtopic Dermatitis and the Medications Used for its Management: Impact on Ocular Health
May 2022 | Volume 21 | Issue 5 | Case Reports | 523 | Copyright © May 2022
Atopic Dermatitis (AD) is one of the most common inflammatory skin conditions. AD is generally characterized by eczematous and pruritic skin lesions, although it can present differently between indivi...
Read MoreLong-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
April 2022 | Volume 21 | Issue 4 | Original Article | 399 | Copyright © April 2022
Background: There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-...
Read MoreLong-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics
April 2022 | Volume 21 | Issue 4 | Original Article | 364 | Copyright © April 2022
Background: Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain. Biologic therapies can vary in their effectiveness and adverse events,...
Read MorePustular and Erythrodermic Psoriasis in Patients Treated With Oral Glucocorticoids: A Survey of United States Dermatologists
April 2022 | Volume 21 | Issue 4 | Features | 427 | Copyright © April 2022
Dermatology dogma has cautioned against the use of orally administered glucocorticoids (OAG) in the treatment of psoriasis, largely due to concerns of life-threatening generalized pustular psoriasis (...
Read MorePustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis
March 2022 | Volume 21 | Issue 3 | Case Reports | 311 | Copyright © March 2022
Dupilumab inhibits T-helper 2 (Th2)-driven inflammation cascade by blocking interleukin-4 (IL-4) and IL-13 signaling, which has been recognized to play a crucial role in the pathogenesis of atopic der...
Read MoreAdjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab
March 2022 | Volume 21 | Issue 3 | Original Article | 235 | Copyright © March 2022
Objective: To examine the effectiveness and safety of adjunctive treatment with calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adult patients with chronic pla...
Read MoreRefractory Dissecting Cellulitis of the Scalp Treated With Risankizumab
March 2022 | Volume 21 | Issue 3 | Case Reports | 313 | Copyright © March 2022
Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by m...
Read MoreBimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 162 | Copyright © February 2022
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.
Objectives: To assess patients' abil...
Read MoreEarly Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
February 2022 | Volume 21 | Issue 2 | Original Article | 122 | Copyright © February 2022
Background: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.
O...
Read MoreIntralesional Mode of Drug Administration in Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 186 | Copyright © February 2022
The use of various conventional systemic and topical therapies in psoriasis has resulted in various major and minor side effects. Hence, we need to switch to intralesional administration of antipsoria...
Read MoreTreatment of Nail Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 146 | Copyright © February 2022
Nail psoriasis has a considerable negative impact on the quality of life by limiting the patient’s household chores, professional activities and social interactions. Treatment for nail psoriasis...
Read MoreNonresponse and Progression of Diffuse Keloids to Dupilumab Therapy
February 2022 | Volume 21 | Issue 2 | Case Reports | 197 | Copyright © February 2022
Th2 cytokines, including IL-4 and IL-13, have been shown to increase TGFβ, promoting fibrosis. A recent study showed keloid improvement in one patient after administration of Dupilumab, an IL-4 r...
Read MoreThe Heterogeneity of Atopic Dermatitis
February 2022 | Volume 21 | Issue 2 | Original Article | 172 | Copyright © February 2022
Background: Recent advances were made in characterizing the clinical heterogeneity of atopic dermatitis (AD).
Objective: To review the clinical domains contribu...
Read MoreAn Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
November 2021 | Volume 20 | Issue 11 | Original Article | 1191 | Copyright © November 2021
Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read More